The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has released its slate of officers for the 2026-2027 term, with Heather Jacene, MD, as president.
Heather Jacene, MDAuntMinnie
Jacene is a senior physician who currently serves as chief of molecular imaging and theranostics at Beth Israel Deaconess Medical Center and clinical director of nuclear medicine/PET-CT at the Dana-Farber Cancer Institute, both in Boston. Her research focuses on using FDG-PET/CT and other novel tracers for characterizing and monitoring the response of cancer to therapy as well as the use of radiopharmaceutical therapy.
SNMMI named Gary Ulaner, MD, PhD, of the Hoag Family Cancer Institute and University of Southern California as president-elect. Jason Lewis, PhD, of Sloan Kettering Institute in New York, was named SNMMI vice president-elect.
Shannon YoungbloodSNMMI
SNMMI Technologist Section (SNMMI-TS) officers for 2026–2027 are Louisiana nuclear medicine technologist and cardiac PET-CT technologist Shannon Youngblood as president, and PET/CT technologist Sara Johnson as president-elect.
Youngblood teaches nuclear medicine imaging sciences at the University of Arkansas for Medical Sciences in Little Rock, AR. Johnson works at Florida Cancer Specialists in Brandon, FL, and also serves as president of the Florida Nuclear Medicine Technologists.
Check out AuntMinnie’s full coverage of SNMMI 2026 on our ShowCast.

![RET-targeted PET tracer highlights neuroendocrine prostate cancer tumors. Representative PET imaging shows strong tumor uptake of the RET-binding peptide tracer [⁶⁸Ga]Ga-DOTA-RET-L7 in a neuroendocrine prostate cancer (NEPC) model, supporting highly specific, high-contrast detection.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/05/screenshot-2026-05-27-205827.278Ys6PYU3.png?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)





![RET-targeted PET tracer highlights neuroendocrine prostate cancer tumors. Representative PET imaging shows strong tumor uptake of the RET-binding peptide tracer [⁶⁸Ga]Ga-DOTA-RET-L7 in a neuroendocrine prostate cancer (NEPC) model, supporting highly specific, high-contrast detection.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/05/screenshot-2026-05-27-205827.278Ys6PYU3.png?auto=format%2Ccompress&fit=crop&h=112&q=70&w=112)








